MEDIMMUNE INC /DE Form 424B7 January 26, 2007 **PROSPECTUS SUPPLEMENT** (To Prospectus dated September 29, 2006)

Filed Pursuant to Rule 424(b)7 Registration No. 333-137720

\$1,150,000,000

\$575,000,000 principal amount 1.375% Convertible Senior Notes due 2011

\$575,000,000 principal amount 1.625% Convertible Senior Notes due 2013

Common Stock

This prospectus supplement covers resales by holders of our 1.375% convertible senior notes due 2011, or the 2011 notes, and our 1.625% convertible senior notes due 2013, or the 2013 notes, and shares of our common stock issueable on conversion of the 2011 notes and the 2013 notes.

This Prospectus Supplement must be read in conjunction with the Prospectus dated September 29, 2006.

Investing in the notes and the common stock issuable upon conversion of the notes involves risks. See Risk factors beginning on page 7 of the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is January 26, 2007.

Edgar Filing: MEDIMMUNE INC /DE - Form 424B7

Selling securityholders

The information in the table below should be considered in addition to the information appearing in the Prospectus under the heading Selling Securityholders and is based on information provided to us by the selling securityholders as of January 25, 2007:

			Principal Amount of Notes Beneficially Owned	Common Stock Issuable Upon Conversion of	Common Stock Owned After Completion of
Name	2011 Notes	2013 Notes	and Offered (1)	the Notes (2)	the Offering(1)
Argentum Multi-strategy Fund Ltd Classic		540,000	540,000	16,182	